Contact
Please use this form to send email to PR contact of this press release:
Voltron Therapeutics, Laidlaw Portfolio Company, Announces Rapid Adaptation of Omicron Variant in Existing COVID vaccine
TO:
Richard Calhoun
Laldlaw & Co
+1 212-953-4937